Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Carlton, Australia.
| Market Capitalization | $63.1375 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.005 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.01 |
| EBITDA | -7,764.779 |
| Profit Margin | 0 |
| Operating Margin TTM | -5.7938 |
| Return on Assets TTM | -0.7323 |
| Return on Equity TTM | -1.7867 |
| Revenue TTM | 1,484.681 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2017-06-30 | 467.76 | 56.99 | 410.77 | |
| 2018-06-30 | 428.39 | 185.62 | 242.77 | |
| 2019-06-30 | 1,219.083 | 199.688 | 1,019.395 | 3,400.113 |
| 2020-06-30 | 532.69 | 200.969 | 331.721 | 5,135.46 |
| 2021-06-30 | 257.347 | 222.75 | 34.597 | 4,700.712 |
| 2022-06-30 | 295.81 | 207.056 | 88.754 | 7,685.196 |
| 2023-06-30 | 435.92 | 203.52 | 232.4 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2017-06-30 | 1,769.81 | 20,015.54 | 3,163.19 | 0 | 1,802.5 | 57,138.71 |
| 2018-06-30 | 98.13 | 16,642.24 | 5,177.52 | 0 | 0 | 57,204.71 |
| 2019-06-30 | 4,313.562 | 16,253.314 | 2,275.826 | 36.206 | 16.909 | 67,385.981 |
| 2020-06-30 | 977.472 | 6,707.497 | 2,572.077 | 81.22 | 4.24 | 67,385.981 |
| 2021-06-30 | 6,717.198 | 10,687.29 | 1,705.607 | 76.493 | 2.742 | 77,003.347 |
| 2022-06-30 | 6,070.967 | 9,212.34 | 1,595.358 | 67.35 | 83,536.397 | |
| 2023-06-30 | 5,175.338 | 5,470.96 | 1,690.87 | 0 | 88,871.66 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2017-06-30 | -854.22 | -678.96 | ||||
| 2018-06-30 | -2,548.03 | -1,671.69 | 98.125 | |||
| 2019-06-30 | -7,795.039 | -2,495.49 | 4,215.437 | 98.125 | 4,313.562 | |
| 2020-06-30 | -9,935.595 | -2,883.73 | -3,336.09 | 4,313.562 | 977.472 | |
| 2021-06-30 | -5,047.465 | -3,544.53 | 5,739.726 | 977.472 | 6,717.198 | |
| 2022-06-30 | -8,620.588 | -6,268.25 | -646.231 | 6,717.198 | 6,070.967 | |
| 2023-06-30 | -10,181.351 | -6,397.65 | -895.63 | 6,070.967 | 5,175.338 |